                         SEQUENCE LISTING

<110>  Yeda Research and Development Co. Ltd
       Schwartz-Eisenbach, Michal
       Cardon-Yaakov, Michal
       Fridkin , Matityahu
 
<120>  modified Kisspeptin peptides and uses thereof

<130>  YEDA-119 PCT

<150>  61/610,698
<151>  2012-03-14

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  para-aminophenylalanine (Pap), NH2C6H4(CH2)1-3CO, Fmoc-Pap, 
       FMS-Pap and C5-C20 acyl-Pap

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Arg, Lys, homo-Arg, homo-Lys or Orn

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Trp, beta-(3-benzothienyl)-L-Ala, 6-methyl Trp, 5-methoxy-Trp, 
       5-hydroxy-Trp and 5-fluoro-Trp

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Tyr, His, O-methyl-Tyr and 2-hydroxy-3-methyl-Phe

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  1

Xaa Xaa Gly Xaa Xaa Xaa Xaa 
1               5           


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  cyclic peptide

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  para-aminophenylalanine (Pap), NH2C6H4(CH2)1-3CO, Fmoc-Pap, 
       FMS-Pap and C5-C20 acyl-Pap

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Arg, Lys, homo-Arg, homo-Lys or Orn

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Trp, beta-(3-benzothienyl)-L-Ala, 6-methyl Trp, 5-methoxy-Trp, 
       5-hydroxy-Trp and 5-fluoro-Trp

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Tyr, His, O-methyl-Tyr and 2-hydroxy-3-methyl-Phe

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  2

Xaa Xaa Gly Xaa Xaa Xaa Xaa 
1               5           


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-Fmoc (FMS)

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Phe, Ile, Leu, Val or Nle

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Arg, Lys, homo-Arg, homo-Lys or Orn

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Trp, beta-(3-benzothienyl)-L-Ala, 6-methyl Trp, 5-methoxy-Trp, 
       5-hydroxy-Trp and 5-fluoro-Trp

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  amidation

<400>  3

Xaa Xaa Gly Xaa Xaa Xaa 
1               5       


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  cyclic peptide

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  para-amino Phe

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Tyr or His

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  4

Xaa Phe Gly Leu Arg Trp Xaa 
1               5           


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Fmoc-Phe or FMS-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  amidation

<400>  5

Xaa Gly Leu Arg Trp 
1               5   


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  para-amino Phe

<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  cyclic peptide

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  6

Xaa Phe Gly Leu Arg Trp Tyr 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  para-amino Phe

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  7

Xaa Phe Gly Leu Arg Trp Tyr 
1               5           


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Fmoc- Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  amidation

<400>  8

Xaa Gly Leu Arg Trp 
1               5   


<210>  9
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  amidation

<400>  9

Cys Tyr Asn Trp Asn Ser Phe Gly Leu Arg Phe Cys 
1               5                   10          


<210>  10
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(12)
<223>  cyclic peptide

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  amidation

<400>  10

Cys Tyr Asn Trp Asn Ser Phe Gly Leu Arg Phe Cys 
1               5                   10          


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  11

Cys Phe Gly Leu Arg Trp Cys 
1               5           


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(7)
<223>  cyclic peptide

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  amidation

<400>  12

Cys Phe Gly Leu Arg Trp Cys 
1               5           


<210>  13
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Fmoc-Tyr

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  amidation

<400>  13

Xaa Asn Trp Asn Ser Phe Gly Leu Arg Phe 
1               5                   10  


<210>  14
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic


<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  amidation

<400>  14

Tyr Asn Trp Asn Ser Phe Gly Leu Arg Phe 
1               5                   10  


